Phaseline

Companies › Regeneron Pharmaceuticals

Regeneron Pharmaceuticals: clinical trials, targets and expected readouts

53 active drug programs in 287 registered trials: 131 Phase 2, 74 Phase 1, 55 Phase 3, 27 Phase 4; Oncology, Metabolic and endocrine, Immunology, Hematology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
dupilumab
Interleukin-4 receptor subunit alpha antagonist
IL4RPhase 4Asthma; Chronic Obstructive Pulmonary Disease (COPD); Atopic Dermatitis; Eosinophilic Esophagitis (EoE) …Nov 2026
Linvoseltamab
anti-B-cell maturation antigen x anti-CD3 bispecific antibody
BCMA, GPRC5D, CD3E, TNFRSF17Phase 4Relapsed/Refractory Multiple Myeloma (RRMM); Relapsed and/or Refractory Multiple Myeloma (RRMM); Relapsed Refractory Multiple Myeloma (RRMM); High Risk Smoldering Multiple Myeloma (HR-SMM) …Aug 2027
Pozelimab
Complement C5 inhibitor
C5Phase 4CHAPLE Disease; Paroxysmal Nocturnal Hemoglobinuria; Age-related Macular Degeneration (AMD); Generalized Myasthenia Gravis …Jul 2028
Aflibercept
Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor
VEGFA, PGFPhase 3Neovascular Age-Related Macular Degeneration; Diabetic Maculopathy; Diabetic Macular Edema (DME); Proliferative Diabetic Retinopathy (PDR) …Jan 2027
REGN7508
Factor XI inhibitor
F11Phase 3Venous Thromboembolism (VTE); Symptomatic Venous Thromboembolism (VTE); Atrial Fibrillation (AF); Peripheral Artery Disease (PAD) …Feb 2027
REGN9933
Factor XI inhibitor
F11Phase 3Atrial Fibrillation (AF); Venous Thromboembolism (VTE); Peripheral Artery Disease (PAD); End-Stage Kidney Disease (ESKD)Feb 2027
Cemiplimab (REGN2810)
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Melanoma; Cutaneous Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma (CSCC); Advanced Non-Small Cell Lung Cancer …Mar 2027
Fianlimab (REGN3767)
Lymphocyte activation gene 3 protein inhibitor
LAG3Phase 3Melanoma; Advanced Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC); Resectable Non-small Cell Lung Cancer …Mar 2027
Mibavademab
Leptin receptor agonist
LEPRPhase 3Monogenic Obesity; Generalized Lipodystrophy; Functional Hypothalamic AmenorrheaJun 2027
ALN-CIDEB
CIDEB inhibitor
CIDEBPhase 3Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis (MASH)Aug 2027
Odronextamab
B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent
MS4A1, CD3E, CD3G, CD3DPhase 3Follicular Lymphoma (FL); Diffuse Large B-cell Lymphoma (DLBCL); B-Cell Non-Hodgkin Lymphoma (B-NHL); Relapsed/Refractory Follicular Lymphoma …Feb 2028
Cemdisiran
Complement C5 mRNA RNAi inhibitor
C5Phase 3Paroxysmal Nocturnal Hemoglobinuria; Age-related Macular Degeneration (AMD); Generalized Myasthenia GravisJul 2028
Garetosmab
Inhibin beta A chain inhibitor
INHBAPhase 3Fibrodysplasia Ossificans Progressiva; ObesityFeb 2029
Carfilzomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 3Relapsed and/or Refractory Multiple Myeloma (RRMM)May 2029
Freneslerbart
Fel d 1 monoclonal antibody
–Phase 3Allergic ConjunctivitisMay 2029
Mevonlerbart
Fel d 1 monoclonal antibody
–Phase 3Allergic ConjunctivitisMay 2029
REGN-2Cat
Dual Fel d 1 monoclonal antibody combination
–Phase 3Allergic ConjunctivitisMay 2029
Olatorepatide (HS-20094)
GLP-1 and GIP receptor agonist
GLP1R, GIPRPhase 2Overweight or ObesityNov 2026
REGN7999
Antibody targeting iron homeostasis in non-transfusion dependent β-thalassemia
–Phase 2Non-Transfusion Dependent Beta-Thalassemia (NTDT)Dec 2026
ALN-ANG3
ANGPTL3 inhibitor
ANGPTL3Phase 2Diabetic Kidney Disease (DKD); Healthy Volunteers With HyperlipidemiaDec 2026
Alirocumab
Subtilisin/kexin type 9 inhibitor
PCSK9Phase 2Hypercholesterolemia; Dyslipidemias; Early PCSK9 Inhibitor on Ventricular Remodling; Acute Myocardial Infarction …Dec 2026
Ubamatamab
Anti-MUC16 monoclonal antibody
MUCIN16Phase 2Ovarian Cancer; Non Small Cell Lung Cancer; Recurrent Ovarian Cancer; SMARCB1-Deficient MalignanciesMay 2027
ALN-PNP
PNPLA3 inhibitor (reduces Patatin-like phospholipase domain-containing protein 3 expressio
PNPLA3Phase 2Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD); Healthy VolunteersAug 2027
BNT116
personalized neoantigen vaccine
–Phase 2Advanced Non-Small Cell Lung CancerJan 2028
REGN13335–Phase 2Pulmonary Arterial Hypertension (PAH)Feb 2028
ALN-HSD
HSD17B13 inhibitor via RNA interference (gene silencing)
HSD17B13Phase 2Metabolic Dysfunction-Associated SteatoHepatitis (MASH)Apr 2028
REGN10597
PD-1-IL2Ra-IL2 immunotherapy
PDCD1, IL2RA, IL2Phase 2Ovarian Cancer; Non Small Cell Lung Cancer; MelanomaJun 2028
Marlotamig
Unclear mechanism - code-named REGN7075
–Phase 2Non Small Cell Lung CancerDec 2029
Trevogrumab
GDF8 (myostatin) inhibitor
MSTNPhase 2Obesity–
REGN7075
OX40 (TNFRSF4) agonist antibody
TNFRSF4Phase 1Advanced Solid TumorsNov 2026
REGN22044–Phase 1Healthy VolunteerFeb 2027
REGN20934
GLP-1 receptor agonist
–Phase 1Overweight or ObesityFeb 2027
REGN9533
Monoclonal antibody targeting anticoagulation pathway in hemodialysis
–Phase 1End-Stage Kidney Disease (ESKD)Apr 2027
89Zr-DFO-REGN5054
Zirconium-89 labeled immunoPET imaging agent targeting PD-L1
–Phase 1Advanced Solid TumorApr 2027
REGN5093 (davutamig)
MET inhibitor
METPhase 1NSCLCJul 2027
REGN5678
Anti-NECTIN4 antibody
NECTIN4Phase 1Metastatic Castration-Resistant Prostate Cancer (mCRPC); Metastatic Castration-resistant Prostate CancerNov 2027
REGN20423–Phase 1Healthy VolunteerAug 2028
REGN5668–Phase 1Ovarian CancerNov 2028
REGN5837–Phase 1B-cell Non-Hodgkins Lymphoma (B-NHL)Feb 2029
DB-OTO
AAV-mediated otoferlin gene delivery
OTOFPhase 1Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)Feb 2029
ALN-SNCA
SNCA mRNA inhibitor (siRNA)
SNCAPhase 1Parkinsons DiseaseJun 2029
Vonsetamig (REGN5459)
CD28 costimulation modulator bispecific antibody
CD28Phase 1Lupus Nephritis (LN)Sep 2029
REGN22530
Protein antagonist that blocks fluid accumulation in the eye to reduce intraocular pressur
–Phase 1Primary Open Angle Glaucoma (POAG)Sep 2029
ALN-CFB
small interfering RNA (siRNA) targeting Complement Factor B
CFBPhase 1Paroxysmal Nocturnal Hemoglobinuria (PNH)Nov 2029
BPX-601
Anti-PSCA CAR-T cell therapy
PSCAPhase 1Prostate CancerFeb 2030
REGN4336
CD3-engaging bispecific antibody with PSMA-targeting domain
–Phase 1Metastatic Castration-resistant Prostate Cancer; Metastatic Castration-Resistant Prostate Cancer (mCRPC)Mar 2030
27T51
MUC16-targeting CAR T cell therapy
MUC16Phase 1Epithelial Ovarian CancerMay 2030
REGN15505
4-1BB (TNFRSF9) agonist with PSMA-targeting domain
–Phase 1Metastatic Castration-Resistant Prostate Cancer (mCRPC)Oct 2030
REGN17235
unclear - SF3B1-directed therapy
–Phase 1Clonal Cytopenia of Undetermined Significance (CCUS)May 2031
ALN-SOD
SOD1 mRNA inhibitor (RNAi therapeutic)
SOD1Phase 1Amyotrophic Lateral Sclerosis (ALS)Mar 2032
REGN17372–Phase 1Relapsed Refractory Multiple Myeloma (RRMM)Sep 2033
REGN7945
B cell maturation antigen (BCMA) targeting agent; mechanism not fully disclosed in registr
–Phase 1Relapsed/Refractory Multiple MyelomaNov 2033
REGV131-LNP1265
Coagulation Factor IX gene insertion therapy delivered via LNP
F9Phase 1Hemophilia BAug 2034

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03480568AlirocumabPhase 3HemodialysisCardiovascularAug 2020
NCT04632433Cemiplimab (REGN2810)Phase 2Cutaneous Squamous Cell CarcinomaOncologyFeb 2023
NCT05537948AlirocumabPhase 4DyslipidemiasMetabolic and endocrineJan 2024
NCT05401786Cemiplimab (REGN2810)Phase 2Carcinoma, Non-Small-Cell LungOncologyNov 2024
NCT05285839dupilumabPhase 4Atopic DermatitisImmunologyDec 2024
NCT05001984AlirocumabPhase 2Intracranial AtherosclerosisCardiovascularApr 2025
NCT04430179dupilumabPhase 2Severe Eosinophilic Chronic Sinusitis Without Nasal PolyposisRespiratoryJul 2025
NCT05553834Cemiplimab (REGN2810)Phase 2Non-small Cell Lung Cancer (NSCLC)OncologySep 2025
NCT05553834AlirocumabPhase 2Non-small Cell Lung Cancer (NSCLC)OncologySep 2025
NCT04731155AlirocumabPhase 4Early PCSK9 Inhibitor on Ventricular RemodlingOtherOct 2025
NCT06850571AfliberceptPhase 4Diabetic MaculopathyMetabolic and endocrineDec 2025
NCT06750471dupilumabPhase 4Nasal PolypsRespiratoryDec 2025
NCT05942222dupilumabPhase 4Chronic Rhinosinusitis With Nasal PolypsRespiratoryApr 2026
NCT06299098TrevogrumabPhase 2ObesityMetabolic and endocrineJun 2026
NCT06299098GaretosmabPhase 2ObesityMetabolic and endocrineJun 2026
NCT05133531PozelimabPhase 3Paroxysmal Nocturnal HemoglobinuriaHematologySep 2026
NCT05133531CemdisiranPhase 3Paroxysmal Nocturnal HemoglobinuriaHematologySep 2026
NCT05574101Cemiplimab (REGN2810)Phase 2Cutaneous Squamous Cell CarcinomaOncologyOct 2026
NCT02612454dupilumabPhase 3Atopic DermatitisImmunologyOct 2026
NCT07431086Olatorepatide (HS-20094)Phase 2Overweight or ObesityMetabolic and endocrineNov 2026
NCT04626635REGN7075Phase 1Advanced Solid TumorsOncologyNov 2026
NCT06665971dupilumabPhase 4Eosinophilic Esophagitis (EoE)ImmunologyNov 2026
NCT03951831Cemiplimab (REGN2810)Phase 2Prostate Cancer MetastaticOncologyNov 2026
NCT05831176dupilumabPhase 2Eosinophilic Gastritis (EoG)GastroenterologyNov 2026
NCT06088771Cemiplimab (REGN2810)Phase 1Non-Small Cell Lung CancerOncologyDec 2026
NCT06088771dupilumabPhase 1Non-Small Cell Lung CancerOncologyDec 2026
NCT06421636REGN7999Phase 2Non-Transfusion Dependent Beta-Thalassemia (NTDT)HematologyDec 2026
NCT06452771ALN-ANG3Phase 1Healthy Volunteers With HyperlipidemiaMetabolic and endocrineDec 2026
NCT04989946Fianlimab (REGN3767)Phase 1Prostate CancerOncologyDec 2026
NCT06623656Cemiplimab (REGN2810)Phase 2Carcinoma, Non-Small-Cell LungOncologyDec 2026
NCT04989946Cemiplimab (REGN2810)Phase 1Prostate CancerOncologyDec 2026
NCT06352073dupilumabPhase 4Eosinophilic EsophagitisGastroenterologyDec 2026
NCT05268107dupilumabPhase 4Atopic DermatitisImmunologyDec 2026
NCT05292404AlirocumabPhase 4Acute Myocardial InfarctionCardiovascularDec 2026
NCT07477704AlirocumabPhase 2HypercholesterolemiaMetabolic and endocrineDec 2026
NCT06477653dupilumabPhase 2Hypereosinophilic SyndromeHematologyDec 2026
NCT04862650Cemiplimab (REGN2810)Phase 2Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8OncologyDec 2026
NCT04315701Cemiplimab (REGN2810)Phase 2Recurrent Skin Squamous Cell CarcinomaOncologyDec 2026
NCT06004986dupilumabPhase 4Atopic DermatitisImmunologyDec 2026
NCT04380038dupilumabPhase 4AsthmaRespiratoryDec 2026
NCT05094570dupilumabPhase 4Nasal PolypsInfectious diseaseDec 2026
NCT05347771dupilumabPhase 2AsthmaRespiratoryDec 2026
NCT04781322AlirocumabPhase 1Alcohol Associated Liver DiseaseImmunologyDec 2026
NCT05535738dupilumabPhase 2Skin InflammationImmunologyJan 2027
NCT07128641OdronextamabPhase 2Follicular LymphomaOncologyJan 2027
NCT06491914AfliberceptPhase 3Neovascular Age-Related Macular DegenerationOphthalmologyJan 2027
NCT03694158dupilumabPhase 4AsthmaRespiratoryJan 2027
NCT02298959AfliberceptPhase 1Clinical Stage IV Cutaneous Melanoma AJCC v8OncologyJan 2027
NCT06860815Cemiplimab (REGN2810)Phase 2Anatomic Stage IV Breast Cancer AJCC v8OncologyJan 2027
NCT04600362dupilumabPhase 2Nummular EczemaImmunologyJan 2027
NCT07526116REGN22044Phase 1Healthy VolunteerOtherFeb 2027
NCT07175428REGN7508Phase 2Atrial Fibrillation (AF)CardiovascularFeb 2027
NCT07175428REGN9933Phase 2Atrial Fibrillation (AF)CardiovascularFeb 2027
NCT07015905REGN7508Phase 3Venous Thromboembolism (VTE)CardiovascularFeb 2027
NCT07594093REGN20934Phase 1Overweight or ObesityMetabolic and endocrineFeb 2027
NCT06705387dupilumabPhase 2Eosinophilic EsophagitisGastroenterologyMar 2027
NCT06246916Fianlimab (REGN3767)Phase 3MelanomaOncologyMar 2027
NCT06246916Cemiplimab (REGN2810)Phase 3MelanomaOncologyMar 2027
NCT04387084Cemiplimab (REGN2810)Phase 1Advanced Malignant Skin NeoplasmOncologyMar 2027
NCT07759167REGN7508Phase 1End-Stage Kidney Disease (ESKD)GenitourinaryApr 2027

The 60 nearest readouts of 287 trials; the rest in the app.

From the company's SEC filings

Cash and short-term investments of $9.3bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PDCD1 (2) CD3E (2) C5 (2) F11 (2) LAG3 (1) GLP1R (1) GIPR (1) MS4A1 (1) CD3G (1) CD3D (1) BCMA (1) GPRC5D (1)

Companies with the same targets

Johnson & Johnson (Janssen) AstraZeneca Roche Eli Lilly Akeso Novo Nordisk Innovent Biologics (Suzhou) Shanghai Henlius Biotech Shenyang Sunshine Pharmaceutical Amgen

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.